are winners!

Top News

Public disclosure of inside information according to article 17 MAR Martinsried/Munich (27.05.2020) - 27 May 2020. The Executive Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard) today decided to adjust its previous 2020 full-year guidance with lower research and development expenses resulting in improved earnings before interest, taxes, depreciation, and amortization (EBITDA). Medigene's core development programs continue despite the ongoing COVID-19 pandemic. Total revenue guidance remains unchanged at EUR 7 - 9 m. Previous guidance for research and development expenses was based on certain conservative ... [ more ]